Eli Lilly Signs $475M Deal with MeiraGTx for Vision-Restoring Gene Therapy
Eli Lilly partners with MeiraGTx in a $475M deal for a breakthrough gene therapy, AAV-AIPL1, designed to restore vision in children born legally blind.
/ 28 items
#LLY↓
Novo Nordisk Shares Jump 3% After Withdrawing from $10 Billion Metsera Bidding War
Novo Nordisk stock climbed up to 3% after the Danish drugmaker withdrew from its heated bidding war with Pfizer over obesity drug startup Metsera, citing financial discipline concerns.
Novo Nordisk Raises Bid Again for Metsera as Takeover Battle with Pfizer Heats Up
Novo Nordisk boosts its offer for obesity startup Metsera, countering Pfizer’s $86.20 per share bid. The bidding war is nearing its end as both pharma giants race to dominate the booming obesity drug market.
Trump Slashes Obesity Drug Prices with Lilly, Novo Nordisk Deals
President Trump announced deals with Eli Lilly and Novo Nordisk to slash GLP-1 obesity drug prices for Medicare/Medicaid and launch TrumpRx.gov. Medicare coverage for these costly treatments begins mid-2026.
Novo Nordisk Cuts Forecast Amid Growing Competition
Novo Nordisk (NVO) lowers 2025 guidance for the fourth time as Wegovy and Ozempic sales slow. New CEO battles Eli Lilly competition while pursuing $10B Metsera acquisition.
Eli Lilly Soars on Blockbuster Weight-Loss Drug Sales, Raises 2025 Outlook
Eli Lilly beats Q3 earnings expectations with $17.6B revenue as Zepbound and Mounjaro drive growth. The Company raises full-year forecast amid booming weight-loss drug market.